Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

353 results about "Transmembrane protein" patented technology

A transmembrane protein (TP) is a type of integral membrane protein that spans the entirety of the cell membrane to which it is permanently attached. Many transmembrane proteins function as gateways to permit the transport of specific substances across the membrane. They frequently undergo significant conformational changes to move a substance through the membrane.

CD19-specific chimeric T cell receptor

The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:ζ receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ζ are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2. The present invention further relates to a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
Owner:CITY OF HOPE

Chimeric antigen receptor

Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.
Owner:MIE UNIVERSITY

Methods Using Pores

The invention relates to a method of identifying an individual nucleotide, comprising (a) contacting the nucleotide with a transmembrane protein pore so that the nucleotide interacts with the pore and (b) measuring the current passing through the pore during the interaction and thereby determining the identity of the nucleotide. The invention also relates to a method of sequencing nucleic acid sequences and kits related thereto.
Owner:OXFORD UNIV INNOVATION LTD

Chimeric immunoreceptor useful in treating human cancers

InactiveUS20090257994A1Negligible toxicityPotent and selectiveBiocidePeptide/protein ingredientsIntracellular signallingMalignancy
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
Owner:CITY OF HOPE

Cd20 antibodies and uses thereof

ActiveUS20110195022A1Improve stabilityImproved ADCC functionAntipyreticAnalgesicsDiseaseCD20
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
Owner:IMMUNOGEN INC

Cd20 antibodies and uses thereof

InactiveUS20110195021A1Improve stabilityImproved ADCC functionSenses disorderAntipyreticDiseaseMalignancy
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
Owner:IMMUNOGEN INC

Membrane for filtering of water

Disclosed are novel water membranes comprising lipid bilayers incorporating functional aqua-porins. The lipid bilayers are arranged in sandwich structures including hydrophilic or hydro-phobic support materials. Also disclosed are water purification devices / systems, including reverse osmosis filtering devices that include membranes having functional aquaporins. Methods of water purification and methods of preparing the membranes are also disclosed. Further, the invention provides for a new type of perforated, hydrophobic polymer film and to membranes containing lipid bilayers having other transmembrane proteins than aquaporins introduced.
Owner:AQUAPORIN AS

Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same

The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of the compounds to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.
Owner:YALE UNIV

Molecular adaptors

The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore.
Owner:OXFORD UNIV INNOVATION LTD

Nanopore device with graphene supported artificial lipid membrane

The invention features the use of graphene, a one atom thick planar sheet of bonded carbon atoms, in the formation of artificial lipid membranes. The invention also features the use of these membranes to detect the properties of polymers (e.g., the sequence of a nucleic acid) and identify transmembrane protein-interacting compounds.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Nanopore device with graphene supported artificial lipid membrane

ActiveUS20130146480A1Rate of movement can be alteredAffect integrityImmobilised enzymesSludge treatmentMembrane protein interactionsCvd graphene
The invention features the use of graphene, a one atom thick planar sheet of bonded carbon atoms, in the formation of artificial lipid membranes. The invention also features the use of these membranes to detect the properties of polymers (e.g., the sequence of a nucleic acid) and identify transmembrane protein-interacting compounds.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Chimeric antigen receptors and immune cells targeting b cell malignancies

The disclosure describes genetically engineered CD37 specific redirected immune effector cells expressing a chimeric antigen receptor (CAR) protein comprising an antigen binding domain derived from an antibody, a single chain antibody or portion thereof that binds CD37; a hinge region; a transmembrane domain and an intracellular signaling domain derived from human CD3ζ or FcRγ; and optionally one or more co-stimulatory intracellular signaling domains The invention includes nucleic acids, vectors and immune effector cells associated with the production of the CAR protein, as well as methods of treating B cell malignancies in humans by cellular immunotherapy.
Owner:BLUEBIRD BIO INC

Transmembrane protein expressed in prostate cancer

A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24PC12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and / or therapeutic target for prostate and other cancers.
Owner:AGENSYS INC

Methods of enhancing translocation of charged analytes through transmembrane protein pores

The invention relates to enhancing translocation of a charged analyte through a transmembrane protein pore. Translocation is enhanced by increasing the net opposing charge of the barrel or channel and / or entrance of the pore. The invention also relates to pores enhanced in accordance with the invention.
Owner:OXFORD UNIV INNOVATION LTD

Stabilized viral envelope proteins and uses thereof

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
Owner:PROGENICS PHARMA INC

Liquid membrane suitable for water extraction

A liquid membrane matrix is disclosed in the form of an aquaporin containing bulk liquid membrane matrix (BLM), wherein said liquid membrane matrix is formed from a solution of an amphiphilic copolymer detergent wherein transmembrane proteins have been functionally incorporated and wherein said matrix further contains a stabilising oil phase. The uses of the membrane matrix include water extraction from liquid aqueous media by forward osmosis, e.g. for desalination of salt water.
Owner:AQUAPORIN AS

Colorectal cancer biomarker

The invention discloses a colorectal cancer biomarker, relating to application of interferon-induced transmembrane protein 1 in inhibition of endogenous retrovirus in colorectal cancer. The hESCs of IFITM1-KO is constructed by using CRISPR / Cas9 technology so as to study the functions of IFITM1. Studies find that the IFITM1-deleted human embryonic stem cell (hESCs) is identical with IFITM1-WT in the aspects of cell proliferation, cell pluripotency, telomere length, telomerase activity and the like. The expression of human endogenous retrovirus in hESCs of IFITM1-KO increases, and expression in para-carcinoma tissue is higher than that in colorectal carcinoma tissue. ChIP-qPCR detection finds that the enrichment of H3K9me3 in hESCs of IFITM1-KO is reduced at the HERVs site. Data shows that the expression level of IFITM1 in hESCs and colorectal carcinoma is in negative correlation to HERVs expression, and the IFITM1 can inhibit the expression of HERVs by regulating epigenetic inheritance.
Owner:NANKAI UNIV

Plasma membrane vesicles comprising functional transmembrane proteins

InactiveUS20170112773A1Enhances and restores cellular gap junction communicationEnhances and restores endogenous CFTR functionOrganic active ingredientsPharmaceutical non-active ingredientsMedicineVesicle/vacuole
Provided herein are methods and compositions for treating a subject in need thereof comprising administering an effective amount of vesicles with functional transmembrane proteins embedded in the plasma membrane. Also provided herein are methods of restoring gap junctional communication comprising the administration of an effective amount of vesicles.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Molecular adaptors

The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore.
Owner:OXFORD UNIV INNOVATION LTD

Chimeric antigen receptor

Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.
Owner:MIE UNIVERSITY

Novel chimeric antigen receptors

The invention relates to chimeric antigen receptor (CAR) scaffolds comprising: a target binding domain; a spacer region; a transmembrane domain; and an intracellular effector domain, wherein the spacer region comprises at least one, or multiples of, domains 2, 3 or 4 or a combination thereof of a CD4 molecule. The invention also relates to polynucleotides and expression vectors encoding said CAR scaffold and immunomodulatory cells comprising said CAR scaffold. The invention also relates to methods of engineering an immunomodulatory cell to comprise said CAR scaffold
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Chlamydia antigens and corresponding DNA fragments and uses thereof

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a nucleotide sequence encoding a transmembrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the transmembrane protein gene product in the host. Modifications are possible within the scope of this invention.
Owner:AVENTIS PASTEUR LTD

Method for amplifying and activating NK (Natural Killer) cells by K562 cells

The invention belongs to the field of immunology and particularly provides a method for amplifying and activating a natural killer cell (NK) in an oriented way under the mutual effect of a K562 cell, which is transfected by transmembranes IL-21, CD14, CD19, CD86 and CD137, and a low-concentration interleukin 2. According to the invention, the method comprises the following steps: transcribing expression carriers, which are used for stably expressing CD8 alpha-interleukin 21, CD14, CD19, CD86 and CD137, by using K562 cell lines, wherein the CD8 alpha is a membrane protein expressed on a cell membrane, and the interleukin 21 is expressed on the cell membrane to become a transmembrane protein after the CD8 alpha gene is connected with the interleukin 21 gene; and then culturing the K562 cell for a section of time; and finally, obtaining a purified K562 cell by using a physical and chemical method and then culturing the NK cell. According to the invention, by using the amplified and activated NK cell, the immunity of the patient can be enhanced, the viruses and bacteria are resisted, and high efficiency is obtained. The method for amplifying and activating the natural killer cell, provided by the invention, medically has wide purposes.
Owner:杭州中赢方舟生物工程有限公司

Systems and methods for predicting the structure and function of multipass transmembrane proteins

The invention provides computer-implemented methods and apparatus implementing a hierarchical protocol using multiscale molecular dynamics and molecular modeling methods to predict the structure of transmembrane proteins such as G-Protein Coupled Receptors (GPCR), and protein structural models generated according to the protocol. The protocol features a combination of coarse grain sampling methods, such as hydrophobicity analysis, followed by coarse grain molecular dynamics and atomic level molecular dynamics, including accurate continuum solvation. Also included are energy optimization to determine the rotation of helices in the (seven-helical) TM bundle, and optimization of the helix translations along their axes and rotational optimization using hydrophobic moment of the helices, to provide a fast and accurate procedure for predicting GPCR tertiary structure.
Owner:CALIFORNIA INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products